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Diabetes Causes the Accelerated Loss of Cartilage During Fracture Repair Which 
Is Reversed by Insulin Treatment 
Abstract 
Fracture healing in diabetic individuals and in animal models of diabetes is impaired. To investigate 
mechanisms by which diabetes may affect fracture healing we focused on the transition from cartilage to 
bone, a midpoint in the fracture healing process. Femoral fractures were induced in mice rendered 
diabetic by multiple low dose streptozotocin treatment and compared to matching normoglycemic mice. 
One group of diabetic animals was treated with slow release insulin to maintain normal serum glucose 
levels. The results indicate that there was relatively little difference in the initial formation of the fracture 
callus on day 10. However, on day 16 the diabetic group had significantly smaller callus, greater loss of 
cartilage and enhanced osteoclastogenesis that was normalized by treatment with insulin when assessed 
by histomorphometric analysis. Chondrocyte apoptosis was significantly higher in diabetic mice and this 
increase was blocked by insulin. These changes were accompanied by diabetes-increased mRNA levels 
of RANKL, TNF-α, and ADAMTS-4 and -5 measured by real-time PCR, which was reversed by insulin 
treatment. On days 16 and 22 bone formation within the callus of diabetic mice was significantly less 
than the normoglycemic and brought to normal levels by insulin treatment. These results suggest that a 
significant effect of diabetes on fracture healing is increased chondrocyte apoptosis and 
osteoclastogenesis that accelerates the loss of cartilage and reduces the anlage for endochondral bone 
formation during fracture repair. That insulin reverses these effects demonstrates that they are directly 
related to the diabetic condition. 
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Diabetes causes the accelerated loss of cartilage during fracture
repair which is reversed by insulin treatment
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aDepartment of Periodontology and Oral Biology, Boston University School of Dental Medicine, Boston, MA
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Abstract
Fracture healing in diabetic individuals and in animal models of diabetes is impaired. To investigate
mechanisms by which diabetes may affect fracture healing we focused on the transition from cartilage
to bone, a midpoint in the fracture healing process. Femoral fractures were induced in mice rendered
diabetic by multiple low dose streptozotocin treatment and compared to matching normoglycemic
mice. One group of diabetic animals was treated with slow release insulin to maintain normal serum
glucose levels. The results indicate that there was relatively little difference in the initial formation
of the fracture callus on day 10. However, on day 16 the diabetic group had significantly smaller
callus, greater loss of cartilage and enhanced osteoclastogenesis that was normalized by treatment
with insulin when assessed by histomorphometric analysis. Chondrocyte apoptosis was significantly
higher in diabetic mice and this increase was blocked by insulin. These changes were accompanied
by diabetes-increased mRNA levels of RANKL, TNF-α, and ADAMTS-4 and -5 measured by real-
time PCR, which was reversed by insulin treatment. On days 16 and 22 bone formation within the
callus of diabetic mice was significantly less than the normoglycemic and brought to normal levels
by insulin treatment. These results suggest that a significant effect of diabetes on fracture healing is
increased chondrocyte apoptosis and osteoclastogenesis that accelerates the loss of cartilage and
reduces the anlage for endochondral bone formation during fracture repair. That insulin reverses
these effects demonstrates that they are directly related to the diabetic condition.
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Introduction
Fracture healing is a complicated multi-phase process that involves the coordinated activity of
many cell types [1]. The healing process is initiated by a hematoma that forms in response to
the disruption of blood vessels. Progenitors are then recruited to the site of injury where they
proliferate and differentiate into chondrocytes and osteoblasts. Chondrocytes produce cartilage
forming a soft cartilaginous callus, which calcifies and protects the injured site. As
chondrocytes undergo apoptosis osteoclasts begin the removal of mineralized cartilage, setting
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the stage for endochondral bone formation by osteoblasts. The bony callus then undergoes
remodeling until the bone reaches it original form.
Bone is affected by diabetes, which causes osteopenia and impairs fracture healing [2,3].
Osteopenia is thought to be a contributing factor to the increased fracture risk observed in
diabetic patients [4–6]. Most studies on osteopenia have focused on impaired bone formation,
which is supported by a decrease in bone mineral density and reduced markers of bone
formation such as serum levels of osteocalcin and alkaline phosphatase [7–9]. Several
mechanisms have been suggested including changes in cell signaling caused by hyperglycemia,
inflammation associated with diabetes, changes in circulating growth factors and endocrine
hormones, greater oxidative stress and increased cell death [2,8,10]. Krakauer et al. have
suggested that patients with diabetes have reduced bone formation and bone accumulation
during growth, while later in life hyperglycemia leads to increased bone resorption and
osteopenia [11]. Recent evidence supports the concept that diabetes can contribute to
osteopenia by increasing osteoclast formation [11–14].
Case reports and clinical investigations have reported that diabetes delays union of healing
fractures and increases healing time in diabetic subjects compared to matched controls [5,15,
16]. Animal models also demonstrate that diabetes leads to the formation of smaller calluses
with decreased bone and cartilage formation, decreased proliferation and differentiation of
osteoblastic cells and chondrocytes and a two-fold reduction in the mechanical strength during
fracture repair in diabetic compared to normoglycemic animals [17–21]. DNA content is
decreased by 40% in healing diabetic fractures compared to controls, an indication that the
diabetic calluses have decreased cellularity [22]. This could be due a decrease in the rate of
cell proliferation associated with decreased growth factor production [23]. In addition, there
is a decrease in the collagen content of the callus of the diabetic animals compared with
normoglycemic animals [19,22]. A decrease in matrix could results from reduced formation
of osteoblasts that produce bone [24].
We previously investigated the impact of diabetes on fracture healing in the tibia. The results
identified a previously unrecognized catabolic effect of diabetes on fracture repair, the
accelerated loss of cartilage in the diabetic group [25]. To investigate further the impact of
diabetes on endochondral bone formation experiments were carried out where fractures were
induced in the femur and the impact of diabeteswas tested by treating mice with slow release
insulin. Histologic and molecular analysis indicated that diabetes caused an increased
osteoclastogenesis and loss of cartilage and increased mRNA levels of several pro-resorptive
factors. Each of these parameters was reversed by treatment with insulin. These studies
represent an important extension of our previous results since they demonstrate that the
catabolic events are specifically related to the diabetic state since they are rescued by insulin
treatment.
Materials and methods
Induction of type 1 diabetes
All experiments were approved by the Boston University Medical Center Institutional Animal
Care and Use Committee (IACUC). Eight week old, male CD-1 mice purchased from Charles
River Laboratories (Wilmington, MA) were rendered diabetic by intraperitoneal injections
(i.p.) of streptozotocin (40mg/kg) (Sigma, St. Louis,MO) in 10mM citrate buffer daily for 5
days [26]. Control mice were treated identically with vehicle alone, 10 mM citrate buffer. A
group of diabetic mice received insulin treatment through slow release insulin implants (Linbit,
Linshin Canada, Toronto, ON) placed subcutaneously. These implants release ~0.1 U of insulin
per day and depending on the weight of the animal, each animal received 4 to 5 implant
according to the manufacturer's instructions. Animals were considered to be diabetic when
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serum glucose levels exceeded 250 mg/dl (Accu-Chek, Roche Diagnostics, Indianapolis, IN)
and were measured weekly. Glycosylated hemoglobin levels were measured at the time of
euthanasia by Glyco-tek affinity chromatography (Helena Laboratories, Beaumont, TX) (Table
1).
Femoral fractures
All studies were performed on male mice that were diabetic for 3 weeks prior to fracture. A
simple transverse closed fracture of the femur was performed in separate animals as previously
described [1,25,27]. In the femoral fractures, the incision was made lateral to the knee to expose
the articular surface of the femur. Access to the medullary canal was gained with a 25 gauge
needle and a 27 gauge spinal needle was inserted for fixation. After closure of the incision, a
fracture was created by blunt trauma. The status of the fracture was confirmed at the time of
euthanasia radiographically and any fractures not consistent with standardized placement
criteria (mid-diaphyseal) or grossly comminuted were excluded. Animals were subsequently
euthanized at 10, 16 and 22 days. Femurs were harvested and most of the associated muscle
and soft connective tissue was gently removed.
Histomorphometric analysis
The femurs with a small amount of surrounding muscle and soft tissues were fixed for 72 h in
cold 4% paraformaldehyde and decalcified for 2 weeks by incubation in cold Immunocal
(Decal Corporation, Congers, NY). After decalcification, specimens were embedded in
paraffin and the fractures were cut in transverse cross-sections at 5 µm and prepared for
staining. To obtain mean values for a given specimen three different histologic sections were
examined that included a histologic section at the fracture line and histologic sections 0.5 mm
proximal and medial to this section. These three sections represent the central region of the
fracture callus. The callus, cartilage and newbone area were measured in sections stained with
hematoxylin and eosin (H & E), safranin-O/fast green, and Masson trichrome respectively.
The area of each tissue was assessed by computer assisted image analysis using Image ProPlus
software (Media Cybernetics, Silver Spring, MD) as previously described [28]. Osteoclast
formation was determined by counting the number of multinucleated, tartrate resistant acid
phosphatase (TRAP) positive cells lining bone or cartilage as previously described [28].
Apoptotic cells were detected by the TUNEL assay (ApopTag® Peroxidase In Situ Apoptosis
Detection Kit, Chemicon International, Temecula, CA). For cartilage area and osteoclast counts
measurements across the callus are presented (0, 0.5 mm proximal and medial and 1.0 mm
proximal and medial of the fracture line) in addition to mean values per specimen. For
histologic analysis the following number of animals were examined per group with each animal
as the unit of measurement, 10 day (normal, n=8, diabetic, n=9, diabetic insulin treated, n=7)
and for 16 and 22 day specimens n=6 for all groups. Measurements were made by one examiner
under blinded conditions, with the results confirmed by a second examiner.
RNA isolation and qPCR
After euthanasia, fracture calluses were carefully dissected removing all muscle and non-callus
tissue and immediately frozen in liquid nitrogen. Total RNA was extracted with Trizol (Life
Technologies, Rockville, MD) from pulverized frozen tissue and further purified by an
RNAeasy MinElute cleanup kit (Qiagen, Valencia, CA). The concentration and integrity of
the extracted RNA was verified by 260 nm/280 nm spectro-photometry and denaturing agarose
gel electrophoresis with ethidium bromide staining. For a given experiment RNA from 3
specimens was combined and TaqMan reagents were used for first-strand cDNA synthesis and
amplification (Applied Biosystems, Foster City, CA) and three sets of experiments were
performed involving a total of 9 mice per data point. Quantitative real time PCR was used to
assess mRNA levels of each genes of interest related to inflammation, osteoclastogenesis,
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matrix degradation and cartilage formation (TNF-α, RANKL, RANK, OPG, ADAMTS-4 and
-5, and collagen-II and -X). Specific primers and probe sets were obtained from Applied
Biosystems. Results were normalized with an 18S ribosomal primer and probe set. Each
experiment was performed three times and the results from the three separate experiments were
combined in order to derive mean values. For a given gene, the expression for each group was
set relative to the value obtained for the normoglycemic control animals on day 10. For
statistical purposes n=3.
Statistical analysis
Data are presented as mean values ± SEM. Two-way ANOVA was used to test whither the
group (normal, diabetic and insulin treated) and/or time point had a significant effect. It was
also used to find statistical interactions between group and time. Interaction was discovered in
some qPCR results (TNF-α, RANKL, TRAP). The Bonferonni method of correction was
applied to this data and the differences were shown to be still significant. One-way ANOVA
with Scheffe's post-hoc test was used to analyze differences between multiple groups at a give
time point andwas also used to analyze differences between time points in the same group.
Results
Callus and cartilage area
To focus on the transition from cartilage to bone specimens were collected at 10, 16 and 22
days after the fracture. Callus size was assessed at the fracture line and 0.5 mm on the proximal
and distal (Fig. 1A). Results from these measurements indicated that the callus size was not
significantly different in the diabetic compared to normoglycemic groups on day 10, but just
missed statistical significance (P=0.07). On day 16 the normoglycemic group had 1.8 fold
larger callus area per section than the diabetic and the insulin treated group had 1.7 fold larger
callus area than the untreated diabetic animals (P<0.05). The smaller callus area in the diabetic
group was maintained on day 22 (P<0.05).
The impact of diabetes and insulin treatment on cartilage was examined. Ten days after fracture
the normoglycemic and insulin treated diabetic animals had 1.6 fold more cartilage area than
the diabetic (P<0.05; Fig. 1B). However, no statistical difference was found when collagen-II
and -X mRNA levels were measured (Fig. 1C). A striking difference was noted over time.
From day 10 to 16 the cartilage area in the diabetic group decreased by 42% (P<0.05) while
the normoglycemic and diabetic insulin treated groups showed no change. On day 16 the
normoglycemic animals had fractures with 2.4 fold more cartilage than the diabetic group and
insulin treatment reversed this deficit (P<0.05). From day 16 to day 22 there was a significant
reduction in cartilage in all three groups (P<0.05). On day 22 the amount of total cartilage in
all groups was small and similar (P>0.05). Changes in cartilage were also examined at 0.5 mm
intervals along the 2 mm length of the callus (Fig. 2). On both days 10 and 16 the area of
cartilage was larger in the normoglycemic group at all sections compared to the diabetic
(P<0.05; Figs. 2A and B). The insulin treated group was also larger than the diabetic group
(P<0.05) and equivalent to the normal.
Osteoclast numbers
On day 10 osteoclast numbers were low in all groups but significantly higher in the diabetic
than the normoglycemic or insulin treated diabetic mice (P<0.05; Fig. 3A). On day 16 there
were 1.75 fold more osteoclasts in the diabetic group compared to the normoglycemic group
(P<0.05), which was reversed by insulin treatment (P<0.05). On day 22 the normoglycemic,
diabetic and diabetic insulin treated groups showed a similar number of osteoclasts. Day 16
specimens were examined in more detail to assess the distribution of osteoclasts over a wider
range of the fracture callus (Fig. 3B). The increase in osteoclast numbers in the diabetic group
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was generally higher across the fracture callus compared to the normoglycemic mice and
insulin treatment reversed this increase across the callus.
mRNA levels of pro-resorptive factors
To gain insight into mechanism that may causes diabetes enhanced osteoclastogenesis mRNA
levels TNF-α, RANKL, RANK, and OPG were measured (Fig. 4). On day 16, TNF-α mRNA
levels were almost 2 fold higher in diabetic fracture calluses compared to the normoglycemic
controls (Fig. 4A; P>0.05). The increase caused by diabetes was reduced to normal levels by
treatment with insulin. On day 22 TNF-α was still significantly higher in the diabetic compared
to the other two groups (P<0.05). RANKL levels were low on day 10 and increased
significantly by day 16 in the diabetic fracture calluses (Fig. 4B; P<0.05). On day 16 RANKL
mRNA levels were almost 2 fold higher in the healing fractures of mice with diabetes versus
normal control mice (P<0.05). Slow release insulin reduced RANKL to normal levels (P>0.05).
In contrast to RANKL, them RNA levels of OPG and RANK did not show any difference
between the groups (Figs. 4C and D; P>0.05).
The mRNA levels of ADAMTS-4 and -5 were examined in each group because of their role
in degrading proteoglycan found in cartilage. On day 10 ADAMTS-4was similar in all three
groups, but was 1.5 fold higher in the diabetic compared to the other two on day 16 (P<0.05).
On day 22, when cartilage was largely gone in the fracture calluses of all groups, the levels
were substantially less (Fig. 5A). The ADAMTS-5 levels were initially similar in all groups
on day 10 but were significantly higher in diabetic mice on 16 compared to the matched normal
control or insulin treated animals (P<0.05; Fig. 5B). On day 22 the levels were similar in all
three groups (P>0.05).
Apoptosis
To gain insight into how diabetes might affect other aspects of cartilage during endochondral
bone formation we quantified the number of apoptotic chondrocytes and compared that to the
total number of apoptotic cells per callus excluding hematopoietic tissue found on day 22
specimens (Fig. 6). The number of apoptotic chondrocytes was more than 5-fold higher in the
diabetic group compared to the normoglycemic (P>0.05; Fig. 6A). Insulin treatment reduced
by number of apoptotic chondrocytes by 60%, which approached but did not reach the level
found in normoglycemic fracture calluses. When the whole callus was examined the diabetic
group showed a 2.5 fold increase in apoptotic cells compared to normoglycemics, which was
significantly reversed with insulin treatment (P<0.05; Fig. 6B).
Bone formation
The amount of new bone was small and equivalent in all groups on day 10 (P>0.05; Fig. 7).
There was a significant increase in bone formation from day 10 to day 16 in the normoglycemic
and diabetic insulin treated groups (P<0.05) but not the diabetic untreated group. On day 16,
the normoglycemic facture calluses had 1.8 fold more bone than the diabetic group (P<0.05).
With insulin treatment, the amount of new bone was restored to match the normoglycemic
group. The difference in amount of bone between the different groups was maintained on day
22 (P<0.05).
Discussion
In patients with diabetes there is an increase risk of fracture [3–6] and impairment in the fracture
healing process [15,16]. Similar findings have been reported in animal models [19,20,22,29].
Diabetic animals exhibit fracture calluses that are smaller in size than those in normal animals
[19,21,23]. We found that at an early time point, day 10, the difference between the diabetic
and control groups just missed statistical significance. While the cartilage area was smaller in
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the diabetic group at this time point the expression of collagen-II and X was similar. This
apparent discrepancy may be due to the impact of greater osteoclastogenesis in the diabetic
group on day 10. A striking observation was the greater reduction in callus area between days
10 and 16 in the diabetic group associated with accelerated loss of cartilage. In contrast the
normoglycemic and insulin treated diabetic mice did not exhibit a similar decrease. These
findings represent an important extension of our previous work because the reversal with
insulin treatment specifically links it to the diabetic condition. Moreover, diabetes resulted in
a two-fold increase in osteoclasts on 16 and a two-fold increase in RANKL and TNF-α. TNF-
α and RANKL are associated with the resorption of mineralized cartilage [30,31]. When
osteoclast number is decreased during endochondral ossification, cartilage is not efficiently
removed [32]. Furthermore, reduced TNF-α signaling or treatment with antibody that inhibits
RANKL causes an increased retention of cartilage [33]. In the diabetic animals the opposite is
observed, increased TNF-α and RANKL expression and the rapid and efficient removal of
cartilage. Moreover, diabetes-increased TNF-α and RANKL was reversed by treatment with
slow release insulin.
The mRNA levels of ADAMTS-4 and -5 were assessed. ADAMTS-4 and -5 play an important
role in degrading the proteoglycan matrix component of cartilage [34–37]. That ADAMTS-4
and -5 are higher in the diabetic group at day 16 would explain the greater removal of
proteoglycan in the diabetic group and the fact that theywere reduced by insulin treatment
indicates that their increase was an outcome of the diabetic condition. Diabetes also increased
the number of apoptotic cells, especially chondrocytes, on day 16. When diabetic animalswere
treated with insulin, the number of apoptotic cells fell to normal levels. The loss of chondrocytes
is thought to be physiologically important since chondrocyte cell death may generate signals
that stimulate resorption of cartilage [38,39].
Diabetic fracture calluses were initially similar in size to the other two groups but became
significantly smaller on days 16 and 22. Insulin treatment reversed this deficit. It is possible
that the loss of cartilage, which serves as an anlagen for endochondral bone formation,
contributes to the reduced bone formation and the reduced amount of bone contributes to the
smaller callus size. The diminished callus size and reduced amount of bone may reduce the
strength of the healing fracture callus, which has been reported by several investigators [17–
20].
We previously reported that the amount of cartilage that formed in tibial calluses were smaller
in the diabetic but that this difference was not statistically significant. In the report here we
found that the initial cartilage formation was statistically significant. It may also be due to slight
differences in time points. However, there was consistency in several catabolic events that
occur during fracture healing that were significantly increased by diabetes and which were
reversed by insulin treatment. Other studies have shown that insulin treatment normalized the
cellular proliferation, chondrogenesis, mineralization and mechanical strength of diabetic
fracture healing [17,40]. The results suggest that many of the defects in fracture healing caused
by diabetes are the direct result of hyperglycemia. However, it is also possible that
hypoinsulinemia also contributes to these catabolic events. For example, insulin is a pro-
survival factor for chondrocytes [29]. By stimulating survival of chondrocytes through insulin
treatment the accelerated loss of cartilage may be affected. Furthermore, insulin has an anabolic
effect on cartilage and bone [29] although the requirement of insulin during bone formation
per se has been question by studies in which genetically modified euglyemic mice that lack
insulin receptors in bone tissue do not exhibit altered bone formation or resorption [41].
Regardless of whether the primary effect of insulin is to reverse hyperglycemia or whether
there are direct effects of insulin on cells, results presented here demonstrate the necessity of
managing serum glucose levels during fracture healing as pointed out by other investigators
[17,20,42,43].
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Fig. 1.
(A) Comparison of callus size in diabetic, normoglycemic and diabetic insulin treated mice
with femoral fracture. Callus area was measured in H&E stained cross-sections obtained from
3 points sampled at the fracture line and 0.5mmproximal and distal and presented as the sum
of these three sites. (B) Comparison of cartilage area in diabetic, normoglycemic and diabetic
insulin treated mice with femoral fracture. The area of cartilage within each callus was
measured in safranin-O/fast green stained sections in the same manner. The individual
measurements were averaged to establish a value of total callus area per animal for each of the
3 time points examined. Data are expressed as mean±SEM. * indicates a significant difference
between normal and diabetic (P<0.05). + indicates significant difference between insulin
treated and untreated diabetic animals (P<0.05). ** indicates a significant difference compared
with the previous time point within a group (P<0.05). (C)mRNA levels of markers of cartilage
formation. mRNA levels were measured by real-time PCR for Collagen 2 and collagen 10.
Each marker was evaluated in 3 separate experiments using 3 mice in each set (total n=3) and
the results are expressed as mean±SEM.
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Fig. 2.
Comparison of cartilage area at 0.5 mm intervals in diabetic, normoglycemic and diabetic
insulin treated mice with femoral fracture. Cartilage area was measured at 5 points sampled at
the fracture line and 0.5 mm and 1.0 mm proximal and distal at the indicated time point. Data
are expressed as mean±SEM. * indicates a significant difference between normal and diabetic
(P<0.05). + indicates a significant difference between insulin treated and untreated diabetic
animals (P<0.05).
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Fig. 3.
Comparison of osteoclast numbers in diabetic, normoglycemic and diabetic insulin treated
mice. (A) The number of osteoclasts was measured in TRAP stained sections and normalized
to cartilage and new bone area. For a given animal three points along a 1 mm length of the
callus were sampled, the individual counts were averaged to establish a value of total osteoclast
number per animal for each of the 3 time points. (B) Detailed comparison of osteoclast numbers
at 0.5 mm intervals in diabetic, normoglycemic and diabetic insulin treated mice with femoral
fracture on day 16. Data are expressed as mean±SEM. * indicates a significant difference
between normal and diabetic (P<0.05). + indicates a significant difference between insulin
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treated and untreated diabetic animals (P<0.05). ** indicates a significant difference compared
with the previous time point within a group (P<0.05).
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Fig. 4.
mRNA levels of cytokines that regulate osteoclastogenesis in femoral fracture. mRNA levels
were measured by real-time PCR for TNF-α, RANKL, RANK and OPG. Each cytokine was
evaluated in 3 separate experiments using 3 mice in each set (total n=3) and the results are
expressed as mean ± SEM. * indicates a significant difference between normal and diabetic
(P<0.05). + indicates a significant difference between insulin treated and untreated diabetic
animals (P<0.05). ** indicates a significant difference compared with the previous time point
within a group (P<0.05).
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Fig. 5.
mRNA levels of enzymes associated with cartilage degradation during fracture repair. mRNA
levels were measured by real-time PCR for ADAMTS-4 and ADAMTS-5. Each enzyme was
evaluated in 3 separate experiments using 3 mice each (n=3) and the results are expressed as
mean ± SEM. *indicates a significant difference between normal and diabetic (P<0.05). +
indicates a significant difference between insulin treated and untreated diabetic animals
(P<0.05). ** indicates a significant difference compared with the previous time point within
a group (P<0.05).
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Fig. 6.
Comparison of apoptotic cell numbers in diabetic, normoglycemic and diabetic insulin treated
mice with femoral fracture. The number of apoptotic cells within each callus was measured in
TUNEL stained sections combined with safranin-O/fast green stain to distinguish chondrocytes
on day 16 specimens. For a given animal a section from the midline of the callus was chosen
for the assay. (A) Apoptotic chondrocytes were counted and normalized to cartilage area. (B)
The total number of apoptotic cells was normalized to callus area. Data are expressed as mean
± SEM. * indicates a significant difference between normal and diabetic (P<0.05). + indicates
a significant difference between insulin treated an untreated diabetic animals (P<0.05).
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Fig. 7.
Comparison of new bone area in diabetic, normoglycemic and diabetic insulin treated mice
with femoral fracture. The area of new bone within each callus was measured in Masson's
trichrome stained sections in the same manner as described in Fig. 1. Data are expressed as
mean ± SEM. * indicates a significant difference between normal and diabetic (P<0.05). +
indicates a significant difference between insulin treated and untreated diabetic animals
(P<0.05). ** indicates a significant difference compared with the previous time point within
a group (P<0.05).
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Table 1
Serum glucose and glycosylated hemoglobin values
Normoglycemic Diabetic Diabetic + insulin
Serum glucose 147 ± 3.2 490 ± 12.9 108 ± 6.4
Glycosylated hemoglobin 6.2 ± 0.18 12.2 ± 0.24 7.4 ± 0.25
Serum glucose levels were measured weekly starting two weeks after induction of diabetes and the mean values are given for each group. Glycosylated
hemoglobin levels were measured at the time of euthanasia from blood obtained by cardiac puncture.
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